Pemetrexed plus platinum outperforms other platinum-based adjuvant chemotherapy regimens for resected stage II-IIIA lung adenocarcinoma: an open-label, historical-control study.

ABSTRACT:

Background

Early-stage lung adenocarcinoma has the potential to achieve long-term survival through radical surgery and appropriate adjuvant therapy. Despite rapid advancements in perioperative treatment strategies, postoperative adjuvant chemotherapy remains critically valuable. However, the optimal adjuvant chemotherapy regimen is yet to be established. Therefore, we initiated this study to evaluate the efficacy and safety of pemetrexed (PEM) plus platinum versus other platinum-based regimes as postoperative adjuvant chemotherapy in patients with stage II-IIIA lung adenocarcinoma after radical surgery to provide further clinical practice evidence.

Methods

We performed a non-randomized, open-label, historical-control study. Seventy-one patients with pathologic stage II-IIIA

SUBMITTER: Ji X 

PROVIDER: S-EPMC12688597 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature